Case ID: 88-078

Web Published: Mar 01, 2011


Solid Dosage Form Antibody or Protein Tablet; Optimised for Ocular Delivery

Available for: Exclusive licensing


The Technology and its Advantages

Antibody therapies are being used to treat highly prevalent eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and other vascular conditions. Therapies such as the blockbuster Lucentis are currently delivered by repeat intraocular injections. Such injections are painful, inconvenient and disliked by patients. Rapid clearance of the antibodies requires repeat injections and results in high dose dumping. Prolonged release can be achieved through an implantable tablet.

We have developed a solid formulation methodology for antibodies and protein therapeutics delivery into the eye. This tablet provides prolonged release of the API and reduces the need for repeat injections.

Market Opportunity

Ocular anti-neovascularisation preparations, used for the treatment of wet AMD, accounted for $1.8bn in sales in 2008. The segment captured 13.4% of the ophthalmic pharmaceutical market, while showing a year on year growth of 29.8%. Lucentis dominated the field with $1.6bn of sales (Business Insights, 2009).

In the pharmaceutical market, monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate (CAGR) of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. Additionally, MAbs are expected to provide the biggest portion of absolute sales growth (Datamonitor 2010). Novel drug delivery methods are increasingly being sought for such therapies.

  • 0
  • 0
  • 0
  • 0